Fezolinetant, sold under the brand name Veozah among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause.[2][8] It is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which is under development by for the treatment of sex hormone-related disorders.[medical citation needed] It is taken by mouth.[2] It is developed by Astellas Pharma which acquired it from Ogeda (formerly Euroscreen) in April 2017.[9][10][11]
The most common side effects include abdominal pain, diarrhea, insomnia, back pain, hot flush and elevated hepatic transaminases.[8]
Fezolinetant was approved for medical use in the United States in May 2023,[8] and in the European Union in December 2023.[3][4] Fezolinetant is the first neurokinin 3 (NK3) receptor antagonist approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes from menopause.[8] The FDA considers it to be a first-in-class medication.[12]
^ ab"Veoza APMDS". Therapeutic Goods Administration (TGA). 6 March 2024. Retrieved 7 March 2024.
^ abcde"Veozah – fezolinetant tablet, film coated". DailyMed. 19 May 2023. Archived from the original on 25 May 2023. Retrieved 24 May 2023.
^ ab"Veoza EPAR". European Medicines Agency (EMA). 7 December 2023. Archived from the original on 26 December 2023. Retrieved 27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ ab"Veoza PI". Union Register of medicinal products. 12 December 2023. Archived from the original on 13 December 2023. Retrieved 26 December 2023.
^"Fezolinetant". Archived from the original on 7 July 2023. Retrieved 7 July 2023.
^"Pharmacokinetic Study of Fezolinetant - an Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects". 15 April 2022. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
^"Fezolinetant". DrugBank.com. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
^ abcd"FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause". U.S. Food and Drug Administration (FDA) (Press release). 12 May 2023. Archived from the original on 13 May 2023. Retrieved 13 May 2023. This article incorporates text from this source, which is in the public domain.
^"Astellas to Acquire Ogeda SA" (Press release). Astellas Pharma. Archived from the original on 5 November 2021. Retrieved 5 November 2021 – via PR Newswire.
^Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, et al. (July 2015). "Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)". ACS Medicinal Chemistry Letters. 6 (7): 736–740. doi:10.1021/acsmedchemlett.5b00117. PMC 4499830. PMID 26191358.
^"Fezolinetant – Ogeda". AdisInsight. Archived from the original on 5 November 2021. Retrieved 5 November 2021.
^New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
Fezolinetant, sold under the brand name Veozah among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause...
Switzerland AG. Depypere H, Lademacher C, Siddiqui E, Fraser GL (July 2021). "Fezolinetant in the treatment of vasomotor symptoms associated with menopause". Expert...
strengthening its late-stage pipeline with Ogeda's drug candidate, fezolinetant. In November 2017, the company announced that it exercised an option...
include cognitive-behavioral therapy, clinical hypnosis, gabapentin, fezolinetant or selective serotonin reuptake inhibitors. These will not improve symptoms...
Match of the Day at the end of the premier league season. 18 December Fezolinetant, a non-hormonal drug used to treat menopause-related hot flushes and...
menopausal women. His research paved the way for the development of fezolinetant, a drug for the treatment of hot flushes in menopause. He also takes...
Global Information
This article incorporates text from this source, which is in the public domain.
